Latest Content

Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery.

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.

New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.